Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the safety and immunogenicity of vaccination with multiple synthetic peptides in participants with advanced breast cancer

Next Previous
X
Search
Trial Profile

Evaluation of the safety and immunogenicity of vaccination with multiple synthetic peptides in participants with advanced breast cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Breast cancer vaccine (Primary) ; Breast cancer vaccine (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 09 Apr 2013 Biomarkers information updated
    • 08 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 May 2008 The expected completion date for this trial is now 1 Apr 2009, according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top